SCHEMBL22233993

SCHEMBL22233993

Cc1c(N)nc2cc(Br)ccc2c1O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.47
PABPC1 P11940 1/20 0.42
ACHE P22303 1/20 0.41
BACE1 P56817 2/20 0.41
HRH4 Q9H3N8 1/20 0.40
F2 P00734 3/20 0.39
HTT P42858 1/20 0.39
PDPK1 O15530 1/20 0.39
JAK2 O60674 1/20 0.39
PTGES O14684 1/20 0.39
PDGFRA P16234 1/20 0.38
CDK5 Q00535 1/20 0.38
TYRO3 Q06418 1/20 0.38
NQO2 P16083 1/20 0.37
PKMYT1 Q99640 2/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24373507 0.83 MPO (0.45) MPOPABPC1ACHEBACE1HRH4
SCHEMBL2725328 0.76 MDM4 (0.45) MPOACHEBACE1HTTPDPK1
SCHEMBL14001902 0.75 HSD17B10 (0.52) ACHEBACE1HTTNQO2RAB9A
SCHEMBL11728816 0.72 PABPC1 (0.61) PABPC1ACHEBACE1HTTPDPK1
SCHEMBL22234179 0.71 NLRP3 (0.52) JAK2NPC1RAB9A
SCHEMBL29522929 0.71 NLRP3 (0.52) JAK2NPC1RAB9A
SCHEMBL22234174 0.70 HTT (0.50) MPOPABPC1ACHEBACE1HRH4
SCHEMBL7427955 0.70 MPO (0.46) MPOACHEBACE1HRH4F2
SCHEMBL6791268 0.70 F2 (0.51) MPOACHEHRH4F2HTT
SCHEMBL5498929 0.70 HRH4 (0.50) MPOPABPC1ACHEBACE1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338228-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC. (US) 2025-06-24 US disclosed
US-20220089566-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY, INC. 2022-03-24 US disclosed
EP-3911642-A1 NLRP3 MODULATORS Innate Tumor Immunity, Inc. (US) 2021-11-24 EP disclosed
CN-113286787-A NLRP3 modulators 先天肿瘤免疫公司 2021-08-20 CN disclosed
WO-2020150116-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY, INC. (US) 2020-07-23 WO disclosed
WO-2020150116-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY, INC. (US) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089566-A1 NLRP3 MODULATORS NLRP3, NLRP1, PYCARD MPO 150/4885PABPC1 1147/4885ACHE 4883/4885
US-12338228-B2 NLRP3 modulators NLRP3, NLRP1, PYCARD MPO 150/4885PABPC1 1147/4885ACHE 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.